Genomma Lab Internacional, S.A.B. de C.V. GNMLF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 949.49M | 936.27M | 913.60M | 926.53M | 957.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 949.49M | 936.27M | 913.60M | 926.53M | 957.40M |
| Cost of Revenue | 348.78M | 346.64M | 339.67M | 339.89M | 349.98M |
| Gross Profit | 600.70M | 589.63M | 573.93M | 586.64M | 607.42M |
| SG&A Expenses | 405.09M | 392.79M | 379.77M | 393.14M | 403.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -611.40K | -1.76M | -1.73M | -5.39M | -2.95M |
| Total Operating Expenses | 753.26M | 737.67M | 717.71M | 727.63M | 750.76M |
| Operating Income | 196.23M | 198.60M | 195.88M | 198.90M | 206.64M |
| Income Before Tax | 131.10M | 128.88M | 126.57M | 122.38M | 139.07M |
| Income Tax Expenses | 40.26M | 41.39M | 42.80M | 38.14M | 43.23M |
| Earnings from Continuing Operations | 90.83 | 87.49 | 83.76 | 84.23 | 95.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -26.80M | -26.80M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.83M | 87.49M | 83.76M | 57.43M | 69.04M |
| EBIT | 196.23M | 198.60M | 195.88M | 198.90M | 206.64M |
| EBITDA | 216.88M | 218.78M | 215.65M | 219.52M | 226.83M |
| EPS Basic | 0.09 | 0.09 | 0.09 | 0.06 | 0.07 |
| Normalized Basic EPS | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 |
| EPS Diluted | 0.09 | 0.09 | 0.09 | 0.06 | 0.07 |
| Normalized Diluted EPS | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 |
| Average Basic Shares Outstanding | 3.92B | 3.90B | 3.91B | 3.92B | 3.88B |
| Average Diluted Shares Outstanding | 3.92B | 3.90B | 3.91B | 3.92B | 3.88B |
| Dividend Per Share | 0.03 | 0.04 | 0.04 | 0.07 | 0.06 |
| Payout Ratio | 59.46% | 48.91% | 49.24% | 69.11% | 42.07% |